A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy Participants

NCT ID: NCT06555601

Last Updated: 2025-12-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 167 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-07-31
• Study Completion Date: 2025-11-24

Brief Summary

The purpose of the study is to evaluate the safety and tolerability of a single ascending dose of UCB3101 in cohorts of healthy male and female study participants.

Conditions

Healthy Participants

Keywords

UCB3101

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Cohort 1

Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 1) or placebo.

Group Type: EXPERIMENTAL

UCB3101

Intervention Type: DRUG

Study participants will receive UCB3101 as prespecified in each cohort.

Placebo

Intervention Type: DRUG

Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Cohort 2

Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 2) or placebo.

Group Type: EXPERIMENTAL

UCB3101

Intervention Type: DRUG

Study participants will receive UCB3101 as prespecified in each cohort.

Placebo

Intervention Type: DRUG

Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Cohort 3

Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 3) or placebo.

Group Type: EXPERIMENTAL

UCB3101

Intervention Type: DRUG

Study participants will receive UCB3101 as prespecified in each cohort.

Placebo

Intervention Type: DRUG

Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Cohort 4

Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 4) or placebo.

Group Type: EXPERIMENTAL

UCB3101

Intervention Type: DRUG

Study participants will receive UCB3101 as prespecified in each cohort.

Placebo

Intervention Type: DRUG

Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Cohort 5

Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 5) or placebo.

Group Type: EXPERIMENTAL

UCB3101

Intervention Type: DRUG

Study participants will receive UCB3101 as prespecified in each cohort.

Placebo

Intervention Type: DRUG

Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Cohort 6

Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 6) or placebo.

Group Type: EXPERIMENTAL

UCB3101

Intervention Type: DRUG

Study participants will receive UCB3101 as prespecified in each cohort.

Placebo

Intervention Type: DRUG

Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Cohort 7

Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 7) or placebo.

Group Type: EXPERIMENTAL

UCB3101

Intervention Type: DRUG

Study participants will receive UCB3101 as prespecified in each cohort.

Placebo

Intervention Type: DRUG

Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Cohort 8

Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 8) or placebo.

Group Type: EXPERIMENTAL

UCB3101

Intervention Type: DRUG

Study participants will receive UCB3101 as prespecified in each cohort.

Placebo

Intervention Type: DRUG

Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Interventions

UCB3101

Study participants will receive UCB3101 as prespecified in each cohort.

Intervention Type: DRUG

Placebo

Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participant must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF.
• Participant must be considered reliable and capable of adhering to the protocol, according to the judgment of the investigator, and capable of communicating satisfactorily with the investigator and complying with all study requirements.

Exclusion Criteria

• Vulnerable individuals (eg, individuals kept in detention, serving soldiers), employees of the Sponsor or the contract research organization (CRO), with direct involvement in the proposed study or other studies under the direction of the investigator or the CRO, as well as family members of the employees or the investigator
• Participant has any medical or psychiatric condition that jeopardize or would compromise the study participant's ability to participate in this study.
• Participant has any clinically significant Electrocardiogram (ECG) abnormalities.
• Participant has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months.
• History or presence of clinically significant respiratory, neurological, gastrointestinal, renal, hepatic, pancreatic, hematological, cardiovascular, musculoskeletal, genitourinary, immunological, or dermatological disorders.
• Participant has had prior history of lymphoma, leukemia, or any malignancy.
• Participant has a clinically significant active infection (eg, sepsis, pneumonia, abscess) or has had a serious infection within 4 weeks before the first dose of IMP.
• Participant has had recurrent (at least 2) clinically relevant infections (eg, tooth abscess, opportunistic infections, boils, etc) in the past 6 months.
• Participant has a history of recurrent headaches, including migraine.
• Participant has evidence or history of significant active bleeding or coagulation disorder.
• Participant has a history of chronic alcohol or drug abuse within 12 months prior to Baseline.
• Participant has a history of skin disorders or extensive tattooing that prevent clear visibility of the skin in case of a hypersensitivity reaction.
• Participant has scheduled surgery between Screening and 1 month after end of study visit.
• Participant has a history of clinically significant back pain, back pathology, and/or back injury that may predispose participant to complications or technical difficulty with lumbar puncture (LP).
• Participant has medical or surgical conditions for which LP is contraindicated.
• Participant is allergic to lidocaine or its derivatives.
• Participant has any clinically relevant brain magnetic resonance imaging (MRI) abnormality at Screening.
• Participant has received any prescription or nonprescription medicines, including any monoclonal antibody (mAb) therapies and over the counter remedies or herbal and dietary supplements (other than vitamins within recommended daily dose limits) within 14 days (or 5 half-lives of the respective drug, whichever is longer) prior to Baseline, other than occasional use of analgesics such as paracetamol or topical nasal corticosteroids for seasonal rhinitis.
• Participant has participated in another study of an investigational medicinal product (IMP) within 90 days (or 5 half-lives of the drug, whichever is longer) prior to Baseline or is currently participating in another study of an IMP.
• Participant has prior exposure to any IMP specifically targeting triggering receptor expressed on myeloid cells 1 (TREM1).
• Participant has received any live vaccination within the 8 weeks prior to Day 1 or is anticipated to do so within 120 days after the final dose of IMP.
• Participant has any clinically relevant abnormal findings in physical examination, laboratory tests, vital signs, or ECG.
• Participant has total bilirubin >upper limit of normal (ULN).
• Participant has current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
• Participant has a positive urine test for substances of abuse.
• Participant has a known active mycobacterium tuberculosis (TB) disease.
• Participant has a known history of active TB involving any organ system unless adequately treated.
• Participant has a positive laboratory test results for human immunodeficiency virus-1/2 antibodies), hepatitis B surface antigen, or hepatitis B core antibody result at Screening.
• Participant has a positive hepatitis C antibody test result at Screening or within 3 months prior to Baseline.
• Participant has clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
• Participant has symptomatic herpes zoster within 3 months prior to Screening.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

UCB Biopharma SRL

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

UCB Cares

Role: STUDY_DIRECTOR

001 844 599 2273 (UCB)

Locations

UP0124 1

Edegem, , Belgium

Countries

Belgium

Other Identifiers

2023-504586-24

Identifier Type: REGISTRY

Identifier Source: secondary_id

U1111-1305-5063

Identifier Type: OTHER

Identifier Source: secondary_id

UP0124

Identifier Type: -

Identifier Source: org_study_id